EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25116279 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mylan R Blomquist und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Alix School of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA. Hauptthemen laut MEDLINE: STAT5 Transcription Factor, Glioblastoma, Quinazolines, Benzodioxoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with few effective treatments. EGFR alterations, including expression of the truncated variant EGFRvIII, are among the most frequent genomic changes in these tumors. EGFRvIII is known to preferentially signal through STAT5 for oncogenic activation in GBM, yet targeting EGFRvIII has yielded limited clinical success to date. In this study, we employed patient-derived xenograft (PDX) models expressing EGFRvIII to determine the key points of therapeutic vulnerability within the EGFRvIII-STAT5 signaling axis in GBM. Our findings reveal that exogenous expression of paralogs STAT5A and STAT5B augments cell proliferation and that inhibition of STAT5 phosphorylation in vivo improves overall survival in combination with temozolomide (TMZ). STAT5 phosphorylation is independent of JAK1 and JAK2 signaling, instead requiring Src family kinase (SFK) activity. Saracatinib, an SFK inhibitor, attenuates phosphorylation of STAT5 and preferentially sensitizes EGFRvIII+ GBM cells to undergo apoptotic cell death relative to wild-type EGFR. Constitutively active STAT5A or STAT5B mitigates saracatinib sensitivity in EGFRvIII+ cells. In vivo, saracatinib treatment decreased survival in mice bearing EGFR WT tumors compared to the control, yet in EGFRvIII+ tumors, treatment with saracatinib in combination with TMZ preferentially improves survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Alix School of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
- Department of Cancer Biology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
- Ventana Medical Systems, Roche Diagnostics, Tucson, AZ 85755, USA.
- Collaborative Center for Translational Mass Spectrometry, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
- Department of Translational Neuroscience, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.
- Department of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
ORCID-Profile: Ritin Sharma, Shannon P Fortin Ensign
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Blomquist, M. R., Eghlimi, R., Beniwal, A., Grief, D., Nascari, D. G., Inge, L., Sereduk, C. P., Tuncali, S., Roos, A., Inforzato, H., Sharma, R., Pirrotte, P., Mehta, S., Fortin Ensign, S. P., Loftus, J. C., & Tran, N. L. (2024). EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116279
Vancouver
Blomquist MR, Eghlimi R, Beniwal A, Grief D, Nascari DG, Inge L, et al. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116279
BibTeX
@article{Blomquist2024,
author = {Blomquist, Mylan R and Eghlimi, Ryan and Beniwal, Angad and Grief, Dustin and Nascari, David G and Inge, Landon and Sereduk, Christopher P and Tuncali, Serdar and Roos, Alison and Inforzato, Hannah and Sharma, Ritin and Pirrotte, Patrick and Mehta, Shwetal and Fortin Ensign, Shannon P and Loftus, Joseph C and Tran, Nhan L},
title = {EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25116279}
}
EUVIMED